GlassScriptPhysician profile
Steven R Macdonald
NPI 1124025036
$14,504.71
in general payments reported to CMS, 2019-2025
32 companies · $8,839 in 2025
The $8,839 reported for 2025 was more than what 98% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $107 · 2021: $309 · 2022: $741 · 2023: $486 · 2024: $3,729 · 2025: $8,839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $789 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,200.00 |
| Food and Beverage | $789.23 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $12,200.00 | 2024-2025 | Bovine Collagen |
| Abbvie INC. | $417.27 | 2019-2023 | |
| Pfizer INC. | $354.17 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $208.00 | 2022 | |
| Hologic Sales and Service, LLC | $202.13 | 2020-2025 | Aptima, Myosure Tissue Removal Device, Novasure |
| Sumitomo Pharma America, INC. | $140.10 | 2023-2025 | Myfembree |
| Avion Pharmaceuticals | $92.88 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.18 | 2019-2023 | |
| Astellas Pharma US INC | $64.99 | 2023 | |
| Innovation Technologies INC | $57.54 | 2023-2025 | Irrisept |
| Lupin INC. | $55.09 | 2019-2021 | |
| Exeltis, USA INC. | $50.37 | 2022-2023 | Slynd |
| Acella Pharmaceuticals, LLC | $49.46 | 2022-2023 | NP Thyroid 60 |
| Avanos Medical | $48.76 | 2019-2021 | |
| Aspira Women'S Health INC | $48.59 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $46.78 | 2019-2022 | |
| Organon LLC | $38.06 | 2022-2024 | Nexplanon |
| Meditrina | $37.82 | 2021-2022 | |
| Channel Medsystems, INC. | $36.26 | 2023 | |
| Sage Therapeutics, LLC | $33.74 | 2019-2025 | Zurzuvae |
| Exact Sciences Corporation | $33.73 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $32.05 | 2022 | |
| Millicent US INC | $29.17 | 2023-2025 | Femlyv, Intrarosa |
| Therapeuticsmd, INC. | $23.36 | 2019-2020 | |
| Dexcom, INC. | $18.88 | 2025 | Dexcom G6 Transmitter |
| Dompe US, INC. | $18.81 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.13 | 2023 | Seglentis |
| Heron Therapeutics, INC. | $14.64 | 2024 | Zynrelef |
| Ethicon US, LLC | $14.32 | 2019 | |
| Convatec INC. | $14.25 | 2022 | |
| Minerva Surgical, INC | $14.18 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Macdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.